SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas

Wang, Peng; Zhang, Jingjing; He, Shuai; Xiao, Boan; Peng, Xiaobin

doi:10.1186/s12935-020-01675-0

Cited by 14 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the detailed tumor-related functions, our in vitro and in vivo data proved that SLC39A1 overexpression can promote gastric adenocarcinoma proliferation, while SLC39A1 knockdown suppressed tumor growth. Consistent with our findings, Wang et al demonstrated that SLC39A1 promoted proliferation of glioma cells and inhibited their apoptosis [ 14 ].…”

Section: Discussionsupporting

confidence: 93%

“…However, in silico analyses did not find its correlation with breast cancer prognosis [ 17 , 18 ]. Recently, Wang's study revealed that SLC39A1 was highly expressed in gliomas and negatively correlated with glioma outcome [ 14 ], highlighting its involvement in different malignancies. As for the detailed tumor-related functions, our in vitro and in vivo data proved that SLC39A1 overexpression can promote gastric adenocarcinoma proliferation, while SLC39A1 knockdown suppressed tumor growth.…”

Section: Discussionmentioning

confidence: 99%

“…Considering that exogenous zinc has significant effect on cell viability and apoptosis [ 11 , 12 ], its potential role in carcinogenesis is attracting more and more attention. Recently, hyper-expression of SLC39A1 has been reported to participate in the malignant progression of hepatocellular carcinoma and glioma [ 13 , 14 ]. However, its role in gastric cancer remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis

Chen

Luo

et al. 2022

Genetics Research

View full text Add to dashboard Cite

Backgrounds. Solute carrier 39A1 (SLC39A1) is an indirect zinc transporter which showed diverse tumor-related functions in different malignancies. Here, we aimed to investigate its expression and role in gastric adenocarcinoma. Methods. A retrospective gastric adenocarcinoma cohort (n = 154) was collected from our hospital to test their tissue expression of SLC39A1 through immunohistochemical staining method. After SLC39A1 overexpression or knockdown, proliferation and invasion assays were conducted for proliferation and invasion estimation, respectively. Xenograft in nude mice was used as the in vivo strategy to validate in vitro findings. Results. Compared with adjacent stomach tissues, gastric adenocarcinoma tissues showed significantly higher SLC39A1 on both mRNA and protein levels. Higher SLC39A1 was observed in patients with larger tumor size ( P = 0.003 ) and advanced tumor stages ( P < 0.001 ). Univariate ( P = 0.001 ) and multivariate analyses ( P = 0.035 ) confirmed the independent prognostic significance of SLC39A1 on gastric adenocarcinoma outcomes. The median survival time was 22.0 months in patients with high-SLC39A1 expression, while up to 57.0 months in those with low-SLC39A1 ( P = 0.001 ). In vitro and in vivo assays demonstrated that overexpressing SLC39A1 could promote gastric cancer growth and invasion, while silencing SLC39A1 led to opposite effects. Conclusions. Aberrant high-SLC39A1 expression can serve as an independent unfavorable prognostic factor for gastric adenocarcinoma. High SLC39A1 is critical for a more aggressive tumor phenotype by promoting cell proliferation and invasion. Therefore, targeting SLC39A1 may provide novel therapeutic insights.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis

Chen

Luo

et al. 2022

Genetics Research

View full text Add to dashboard Cite

show abstract

“…While an increase in SLC39A1 mRNA levels were not observed in all individuals from the treated group [349], comparable results have been obtained in humans by another group, demonstrating an increased ZIP1 mRNA expression in lymphocytes in an Australian elderly population supplemented with Zn [350]. Lastly, ZIP1 is associated with various cancers [351][352][353], including pancreatic [287] and prostate [354][355][356][357] cancer.…”

Section: Zip1 (Slc39a1)supporting

confidence: 81%

Impact of Zinc Transport Mechanisms on Embryonic and Brain Development

Willekens

Runnels

2022

Nutrients

View full text Add to dashboard Cite

The trace element zinc (Zn) binds to over ten percent of proteins in eukaryotic cells. Zn flexible chemistry allows it to regulate the activity of hundreds of enzymes and influence scores of metabolic processes in cells throughout the body. Deficiency of Zn in humans has a profound effect on development and in adults later in life, particularly in the brain, where Zn deficiency is linked to several neurological disorders. In this review, we will summarize the importance of Zn during development through a description of the outcomes of both genetic and early dietary Zn deficiency, focusing on the pathological consequences on the whole body and brain. The epidemiology and the symptomology of Zn deficiency in humans will be described, including the most studied inherited Zn deficiency disease, Acrodermatitis enteropathica. In addition, we will give an overview of the different forms and animal models of Zn deficiency, as well as the 24 Zn transporters, distributed into two families: the ZIPs and the ZnTs, which control the balance of Zn throughout the body. Lastly, we will describe the TRPM7 ion channel, which was recently shown to contribute to intestinal Zn absorption and has its own significant impact on early embryonic development.

show abstract

“…Wang et al demonstrated that SLC39A1 overexpression promotes tumor progression and correlates with unfavorable clinical outcomes in glioma. 14 In addition, downregulation of SLC39A1 impairs the accumulation of zinc in tumor cells, thereby promoting the malignant phenotype of prostate cancer. 15 , 16 However, little is known about the regulatory mechanism of SLC39A1 in HCC progress.…”

Section: Introductionmentioning

confidence: 99%

SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression

Ma¹,

Zhuang²,

Wang³

et al. 2022

JHC

View full text Add to dashboard Cite

Background: Solute carrier family 39 member 1 (SLC39A1) has been identified as a zinc ion transport protein that possesses oncogenic properties in various types of cancers. However, its potential function in hepatocellular carcinoma (HCC) remains unknown. This study aimed to investigate the expression profile and potential mechanisms of SLC39A1 in HCC. Methods: SLC39A1 expression was analyzed using multiple databases. The clinical significance and associated biological pathways of SLC39A1 were investigated using bioinformatics analysis. Potential correlations between SLC39A1 expression and tumor immunity in HCC were also evaluated using single-sample gene set enrichment analysis (GSEA). Sixty paired HCC samples were used to verify the expression pattern of SLC39A1. In vitro studies were performed to investigate the oncogenic effects of SLC39A1 in HCC. Western blot analysis was conducted to further investigate the possible involved signaling pathways. Results:The overexpression of SLC39A1 in HCC was determined by bioinformatics analysis and was confirmed in tissues from our center. SLC39A1 overexpression was also significantly correlated with worse prognosis, advanced TNM stage, and histological grade. GSEA analysis demonstrated that SLC39A1 overexpression was involved in various tumor-related pathways, such as the cell cycle and Wnt signaling pathway. SLC39A1 knockdown repressed the proliferation, invasion, and migration abilities of HCC cells. Furthermore, SLC39A1 knockdown decreased the expression of the tumor progression-related proteins (eg, cyclin D1 and MMP2) and Wnt signaling pathway-related proteins (eg, Wnt3A and β-catenin). In addition, SLC39A1 overexpression may be associated with impaired tumor immunity in HCC, as evidenced by the increased infiltration of Th2 cells and reduced infiltration of cytotoxic cells. Conclusion: These findings preliminarily suggested the crucial effect of SLC39A1 overexpression on HCC tumor progression and immunosuppression, suggesting its potential as a novel prognostic and therapeutic target in HCC.

show abstract

SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas

Cited by 14 publications

References 41 publications

Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis

Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis

Impact of Zinc Transport Mechanisms on Embryonic and Brain Development

SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression

Contact Info

Product

Resources

About